No Data
No Data
J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Regeneron Pharma Is Maintained at Overweight by JP Morgan
Regeneron Pharmaceuticals Analyst Ratings
Express News | Regeneron Pharmaceuticals Inc : JP Morgan Cuts Target Price to $1,000 From $1,100
Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent
Express News | Dupixent® (Dupilumab) Approved as the First-Ever Biologic Medicine in Japan for Patients With Chronic Obstructive Pulmonary Disease (Copd)